Aimee Crombie, Ph.D. is Vice President of R&D Operations at Prelude Therapeutics. Prior to joining Prelude, she was Vice President of Research at Trevena, Inc. where she oversaw drug discovery activities supporting target and hit identification, chemical lead optimization, and drug candidate selection. Dr. Crombie has contributed to the discovery of several small molecule including oliceridine and TRV734, which are being developed for the management of moderate-to-severe pain. Among other projects, she also led the discovery of TRV250, a biased agonist of the δ opioid receptor that is being developed for the treatment of migraine. Prior to joining Trevena, Dr. Crombie was a member of the Discovery Medicinal Chemistry group at Pfizer (formerly Wyeth) where she contributed to research programs in a variety of therapeutic areas including oncology, inflammation, neuroscience, cardiovascular, and musculoskeletal diseases. Dr. Crombie received her B.S. in Chemistry from the University of Pittsburgh and her Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.